Search type

Query format

Minimum Tanimoto similarity

Fingerprint

doxifluridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
uridine derivatives used as antiviral agents and as antineoplastics	958	3094-09-5

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

5-DFUR
doxifluridine
flutron
furtulon

Molecular weight: 246.19
Formula: C9H11FN2O5
CLOGP: -1.19
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 99.10
ALOGS: -0.81
ROTB: 1

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	69.63 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.28 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.61 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.35 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,TEK	18
kinase-selectivity-class	GRK2,MAP2K6,MAP3K14,PDK1	4
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1987	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	87.62	79.40	16	344	6338	90621749

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	150.20	85.36	29	510	12666	110576094

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D000963	Antimetabolites
MeSH PA	D000964	Antimetabolites, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D009676	Noxae
MeSH PA	D019167	Appetite Stimulants
CHEBI has role	CHEBI:35221	antimetabolite
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:50266	prodrug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Primary malignant neoplasm of gastrointestinal tract	indication	363745004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.88	acidic
pKa2	13.11	acidic
pKa3	13.83	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thymidylate synthase	Enzyme	P04818	TYSY_HUMAN					WOMBAT-PK

External reference:

ID	Source
D01309	KEGG_DRUG
C0048808	UMLSCUI
CHEBI:31521	CHEBI
CHEMBL1130	ChEMBL_ID
DB12947	DRUGBANK_ID
C025034	MESH_SUPPLEMENTAL_RECORD_UI
18343	PUBCHEM_CID
4913	INN_ID
V1JK16Y2JP	UNII
010903	NDDF
V1JK16Y2JP	INXIGHT DRUGS

Pharmaceutical products:

None